Key Points
- Invus Global Management purchased 1,538,462 shares of Lexicon Pharmaceuticals at an average price of $1.30 per share for about $2.0 million, a transaction filed with the SEC that represents a new (∞) increase in its position.
- Lexicon is trading around $1.27 with a market cap of $461.6M, posted a recent quarter beating revenue and EPS estimates despite negative margins, and analysts have an average rating of "Hold" with a consensus target price of $3.23.
- Institutional investors own 74.7% of the stock, and the company’s most advanced product is telotristat ethyl (XERMELO) for carcinoid syndrome diarrhea.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) Director Invus Global Management, Llc acquired 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, February 2nd. The shares were bought at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the transaction, the director owned 1,538,462 shares in the company, valued at approximately $2,000,000.60. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Lexicon Pharmaceuticals Trading Down 0.8%
NASDAQ:LXRX opened at $1.27 on Thursday. The company has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.28. The stock has a market cap of $461.61 million, a price-to-earnings ratio of -6.68 and a beta of 0.98. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $1.83.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The company had revenue of $14.18 million during the quarter, compared to the consensus estimate of $5.81 million. Equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.
Wall Street Analyst Weigh In
LXRX has been the subject of a number of research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded Lexicon Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, November 15th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Lexicon Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $3.23.
Read Our Latest Research Report on LXRX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP bought a new stake in Lexicon Pharmaceuticals in the second quarter worth $26,000. R Squared Ltd bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth about $28,000. Vermillion & White Wealth Management Group LLC grew its position in Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 26,000 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at about $51,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Lexicon Pharmaceuticals by 77.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 28,594 shares during the last quarter. Institutional investors own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
